UDP-glucuronosyltransferase expression in mouse liver is increased in obesity- and fasting-induced steatosis.
UDP-glucuronosyltransferases (Ugt) catalyze phase II conjugation reactions with glucuronic acid, which enhances chemical polarity and the elimination from the body. Few studies have addressed whether Ugt expression and activity are affected by liver disease, such as steatosis. The purpose of this study was to determine whether steatosis induced by obesity or fasting could affect liver Ugt mRNA expression and activity. Male C57BL/6J and Lep(ob/ob) (ob/ob) mice were fed ad libitum or food was withheld for 24 h. In steatotic livers of ob/ob mice, Ugt1a1, -1a6, -1a9, -2a3, -3a1, and -3a2 mRNA expression increased. Fasting, which also induced steatosis, increased hepatic Ugt1a1, -1a6, -1a7, -1a9, -2b1, -2b5, -2a3, -3a1, and -3a2 mRNA expression in mouse liver. Likewise, acetaminophen glucuronidation increased by 47% in hepatic microsomes from ob/ob mice compared with that in C57BL/6J mice, but not after fasting. In both steatosis models, Ugt induction was accompanied by increased aryl hydrocarbon receptor, constitutive androstane receptor (CAR), peroxisome proliferator-activated receptor (PPAR)-α, pregnane X receptor, nuclear factor (erythroid-derived 2)-like 2 (Nrf2), and peroxisome proliferator-activated receptor-γ coactivator-1α mRNA expression. In addition, fasting increased CAR, PPAR, and Nrf2 binding activity. The work points to hepatic triglyceride concentrations corresponding with nuclear receptor and Ugt expression. The findings indicate that steatosis significantly alters hepatic Ugt expression and activity, which could have a significant impact on determining circulating hormone levels, drug efficacy, and environmental chemical clearance.
Department of Biomedical and Pharmaceutical Sciences, University of Rhode Island, 41 Lower College Rd., Kingston, RI 02881, USA.
Jialin
J
Xu
Supriya R
SR
Kulkarni
Liya
L
Li
Angela L
AL
Slitt
D000082:Acetaminophen / Q000031:analogs & derivatives / Q000378:metabolism; D018712:Analgesics, Non-Narcotic / Q000378:metabolism; D000818:Animals; D002478:Cells, Cultured; D004790:Enzyme Induction; D005215:Fasting / Q000009:adverse effects*; D005234:Fatty Liver / Q000209:etiology / Q000378:metabolism* / Q000473:pathology; D005508:Food Deprivation; D020719:Glucuronides / Q000378:metabolism; D014453:Glucuronosyltransferase / Q000235:genetics / Q000378:metabolism*; D007527:Isoenzymes / Q000235:genetics / Q000378:metabolism; D008099:Liver / Q000201:enzymology* / Q000378:metabolism / Q000473:pathology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D008820:Mice, Obese; D008862:Microsomes, Liver / Q000201:enzymology / Q000378:metabolism; D009765:Obesity / Q000378:metabolism* / Q000473:pathology / Q000503:physiopathology; D012333:RNA, Messenger / Q000378:metabolism; D018160:Receptors, Cytoplasmic and Nuclear / Q000235:genetics / Q000378:metabolism; D015854:Up-Regulation
D018712:Analgesics, Non-Narcotic; D020719:Glucuronides; D007527:Isoenzymes; D012333:RNA, Messenger; D018160:Receptors, Cytoplasmic and Nuclear; D000082:Acetaminophen; C037386:acetaminophen glucuronide; D014453:Glucuronosyltransferase